Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EBT (2020 - 2023)

Cullinan Therapeutics has reported EBT over the past 4 years, most recently at -$39.7 million for Q4 2023.

  • Quarterly results put EBT at -$39.7 million for Q4 2023, down 37.1% from a year ago — trailing twelve months through Dec 2023 was -$169.2 million (down 211.83% YoY), and the annual figure for FY2025 was -$219.9 million, down 31.3%.
  • EBT for Q4 2023 was -$39.7 million at Cullinan Therapeutics, down from -$39.2 million in the prior quarter.
  • Over the last five years, EBT for CGEM hit a ceiling of $240.1 million in Q2 2022 and a floor of -$58.1 million in Q1 2023.
  • Median EBT over the past 4 years was -$28.2 million (2022), compared with a mean of -$9.1 million.
  • Peak annual rise in EBT hit 1560.76% in 2022, while the deepest fall reached 2387.53% in 2022.
  • Cullinan Therapeutics' EBT stood at -$29.1 million in 2020, then fell by 17.57% to -$34.2 million in 2021, then rose by 15.38% to -$28.9 million in 2022, then tumbled by 37.1% to -$39.7 million in 2023.
  • The last three reported values for EBT were -$39.7 million (Q4 2023), -$39.2 million (Q3 2023), and -$32.2 million (Q2 2023) per Business Quant data.